Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 98

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 98
---
 Proposal No. 13 to approve the CVR Agreement. •“FOR” Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Reasons for the Merger (Page 133) In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, the NLS Board took into account information presented during the process and considered the following factors that it viewed as supporting its decision to approve the Merger Agreement: Strategic Considerations •Advantages •Complementary Strengths: The Merger enables the combined company to integrate its diverse expertise, technologies, and product pipelines, leading to more holistic solutions in its target market. Specifically: •Technology & R&D Synergies: NLS and Kadimastem bring together distinct but complementary research capabilities, accelerating innovation and increasing the potential for breakthrough developments. •Product Portfolio Expansion: The Merger aligns differentiated but synergistic offerings, allowing for enhanced cross -productfunctionality and bundling opportunities, particularly regarding the treatment/cure of diabetes. •Operational Expertise: NLS and Kadimastem leverage specialized knowledge in distinct areas (e.g., manufacturing, commercialization, regulatory processes, R&D) to create a stronger, more agile operational structure. •Go -to-Market& Customer Reach: Combining resources broadens market access, enabling entry into new geographical regions and a more diverse customer base. •Expansion of Market Reach: The Merger allows the combined company to increase market penetration and geographical coverage, creating a stronger competitive presence. Specifically: •Expanded R&D Influence & Industry Presence: While NLS and Kadimastem currently lack established salesforces or distribution channels, the Merger: •Strengthens Scientific Credibility: A larger combined research team with broader expertise enhances reputation within the scientific and investment communities. •Improves Attractiveness for Partnerships: The combined company is more appealing for collaborations with pharma, biotech firms, government agencies, and grant funders. •Increases Visibility in Academic & Regulatory Circles: The Merger can lead to more publications, conference presentations, and regulatory engagement, positioning the combined company as a future market leader. •Attracts More Investors & Funding: A combined pipeline and stronger IP portfolio create a more compelling investment case for investors, as well as non -dilutivegrants. •Accelerates Potential Market Entry: Shared R&D efforts may reduce time -to-market, increasing the likelihood of a successful transition from preclinical to clinical stages. •St